This article is part of Innovative Treatment for Congenital Heart Disease at Every Stage of Life.
Researchers in NYU Langone’s Pediatric Congenital Heart Program are at the forefront of investigating new approaches for diagnosing and treating patients with congenital heart disease (CHD), through both basic research and clinical trials.
In 2018, Achiau Ludomirsky, MD, professor of pediatrics, won the Echovation Challenge as lead developer of the Ultrasound Translator, which uses artificial intelligence and deep-learning algorithms to automatically assess and analyze cardiac images, whether prenatal, pediatric, or adult.
The handheld device is designed to bridge the gap between the ultrasound expert and non-expert, improving workflow and patient care in both established echo labs and point-of-care settings.
Areas of investigation also include three-dimensional printing and airway virtual reality that precisely assesses preintervention anatomy, the impact of ischemic arrest on pulmonary valve implantation, the pathogenesis of diseases such as Barth and Marfan syndrome, and the effects of air pollution on the fetal heart.